title: S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease.
abstract: BACKGROUND
  The lysosphingolipid sphingosine 1-phosphate (S1P) is carried in the blood in association with lipoproteins, predominantly high density lipoproteins (HDL). Emerging evidence suggests that many of the effects of HDL on cardiovascular function may be attributable to its S1P cargo.
  
  
  METHODS
  Here we have evaluated how levels of S1P and related sphingolipids in an HDL-containing fraction of human serum correlate with occurrence of ischemic heart disease (IHD). To accomplish this we used liquid chromatography-mass spectrometry to measure S1P levels in the HDL-containing fraction of serum (depleted of LDL and VLDL) from 204 subjects in the Copenhagen City Heart Study (CCHS). The study group consisted of individuals having high serum HDL cholesterol (HDL-C) (females:≥ 73.5 mg/dL; males:≥ 61.9 mg/dL) and verified IHD; subjects with high HDL-C and no IHD; individuals with low HDL-C (females:≤ 38.7 mg/dL; males:≤ 34.1 mg/dL) and IHD, and subjects with low HDL-C and no IHD.
  
  
  RESULTS
  The results show a highly significant inverse relationship between the level of S1P in the HDL-containing fraction of serum and the occurrence of IHD. Furthermore, an inverse relationship with IHD was also observed for two other sphingolipids, dihydro-S1P and C24:1-ceramide, in the HDL-containing fraction of serum. Additionally, we demonstrated that the amount of S1P on HDL correlates with the magnitude of HDL-induced endothelial cell barrier signaling.
  
  
  CONCLUSIONS
  These findings indicate that compositional differences of sphingolipids in the HDL-containing fraction of human serum are related to the occurrence of IHD, and may contribute to the putative protective role of HDL in IHD.
authors.affiliation: Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC 29425, USA. argravek@musc.edu
authors.forename: Kelley M
authors.initials: KM
authors.lastname: Argraves
authors.forename: Amar A
authors.initials: AA
authors.lastname: Sethi
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Gazzolo
authors.forename: Brent A
authors.initials: BA
authors.lastname: Wilkerson
authors.forename: Alan T
authors.initials: AT
authors.lastname: Remaley
authors.forename: Anne
authors.initials: A
authors.lastname: Tybjaerg-Hansen
authors.forename: Børge G
authors.initials: BG
authors.lastname: Nordestgaard
authors.forename: Sharon D
authors.initials: SD
authors.lastname: Yeatts
authors.forename: Katherine S
authors.initials: KS
authors.lastname: Nicholas
authors.forename: Jeremy L
authors.initials: JL
authors.lastname: Barth
authors.forename: W Scott
authors.initials: WS
authors.lastname: Argraves
mesh_terms: D002465:Cell Movement / Q000187:drug effects; D002518:Ceramides / Q000097:blood; D005591:Chemical Fractionation; D002853:Chromatography, Liquid; D003718:Denmark / Q000453:epidemiology; D017097:Electric Impedance; D042783:Endothelial Cells / Q000187:drug effects / Q000473:pathology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000473:pathology; D005260:Female; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood*; D008246:Lysophospholipids / Q000097:blood* / Q000494:pharmacology; D008297:Male; D013058:Mass Spectrometry; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood* / Q000453:epidemiology*; D012372:ROC Curve; D013107:Sphingolipids / Q000097:blood; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology
chemical_list: D002518:Ceramides; D008075:Lipoproteins, HDL; D008246:Lysophospholipids; D013107:Sphingolipids; C060504:dihydrosphingosine 1-phosphate; C060506:sphingosine 1-phosphate; D013110:Sphingosine